Keros Therapeutics, Inc. (KROS) vs Anbio Biotechnology Class A Ordinary Shares (NNNN)

A side-by-side comparison of Keros Therapeutics, Inc. and Anbio Biotechnology Class A Ordinary Shares across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Keros Therapeutics, Inc. logo
KROS
Keros Therapeutics, Inc.
$226M
$11.42HealthcareDelayed quote: Oct 6, 2026, 11:45 AM EDT
Anbio Biotechnology Class A Ordinary Shares logo
NNNN
Anbio Biotechnology Class A Ordinary Shares
$218M
$4.96HealthcareDelayed quote: Oct 6, 2026, 11:43 AM EDT

Total return — KROS vs NNNN

growth of $100 · dividends reinvested · last 2y
KROS +8.6% (+4.2%/yr)NNNN -16.3% (-8.5%/yr)KROS compounded faster over this window
200400600800Start $1002026$109$84
KROS NNNN

KROS vs NNNN: by the numbers

  • •KROS is the larger company ($226M vs $218M market cap).
  • •NNNN is profitable (74.06% net margin) while KROS runs a net loss (-553.88%).

Metrics side by side

Valuation

MetricKROSNNNN
P/S ratio15.08N/A
P/B ratio0.867.22

Profitability

MetricKROSNNNN
Gross margin94.68%87.24%
Operating margin28.94%66.70%
Net margin-553.88%74.06%
ROE-31.70%21.24%
ROIC-36.49%19.13%

Growth (annualized)

MetricKROSNNNN
Revenue CAGR (5Y)172.50%N/A
Total return CAGR (5Y)-21.98%N/A

Frequently asked

Is KROS or NNNN more profitable?
NNNN runs the higher net margin — KROS at -553.88% versus NNNN at 74.06%.

Go deeper

Full KROS analysisFull NNNN analysisInteractive comparison tool

Dig into the metrics

Keros Therapeutics ROEAnbio Biotechnology Class A Ordinary Shares ROEKeros Therapeutics operating marginAnbio Biotechnology Class A Ordinary Shares operating marginKeros Therapeutics revenue growthAnbio Biotechnology Class A Ordinary Shares revenue growthKeros Therapeutics free cash flowAnbio Biotechnology Class A Ordinary Shares free cash flow

Keros Therapeutics & Anbio Biotechnology Class A Ordinary Shares appear in these rankings

Fastest Revenue Growth StocksHighest ROIC StocksHighest Operating Margin Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.